| Phase 3 |
| NCT05501886 |
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the… |
Breast Cancer |
Active, Not Recruiting |
| NCT05646862 |
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With… |
Breast Cancer |
Active, Not Recruiting |
| NCT04208178 |
Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance… |
Advanced HER2+Breast Cancer |
Active, Not Recruiting |
| NCT05038735 |
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants… |
Breast Cancer |
Active, Not Recruiting |
| Phase 2/3 |
| NCT05948943 |
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a… |
Lymphatic Malformations |
Recruiting |
| Phase 2 |
| NCT05933395 |
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor |
Advanced Breast Cancer |
Recruiting |
| NCT05577754 |
Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult… |
Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP) |
Recruiting |
| NCT05983159 |
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular… |
Slow-Flow Vascular Malformation |
Recruiting |
| NCT05564377 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced… |
Advanced Malignant Solid Neoplasm |
Recruiting |
| NCT06997588 |
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics… |
PIK3CA-related Overgrowth Spectrum (PROS) |
Recruiting |
| NCT04762979 |
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression… |
Hormone Receptor Positive Breast Carcinoma |
Active, Not Recruiting |
| NCT05154487 |
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer |
Endometroid Endometrial Cancer |
Active, Not Recruiting |
| NCT04980833 |
Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With… |
PIK3CA-related Overgrowth Spectrum (PROS) |
Active, Not Recruiting |
| NCT07543822 |
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs |
Vascular Anomalies |
Active, Not Recruiting |
| NCT04589650 |
Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult… |
PIK3CA-related Overgrowth Spectrum (PROS) |
Active, Not Recruiting |
| NCT05392608 |
SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) |
Neoplasm, Breast |
Active, Not Recruiting |
| NCT04524000 |
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in… |
Advanced Breast Cancer |
Active, Not Recruiting |
| NCT04544189 |
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant… |
Breast Neoplasms |
Active, Not Recruiting |
| Phase 1/2 |
| NCT05563220 |
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various… |
Breast Cancer |
Recruiting |
| NCT05230810 |
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic… |
HER2-positive Metastatic Breast Cancer |
Active, Not Recruiting |
| NCT01872260 |
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer |
Breast Cancer |
Active, Not Recruiting |
| Phase 1 |
| NCT06354088 |
Human Models of Selective Insulin Resistance: Alpelisib, Part I |
Insulin Resistance |
Recruiting |
| NCT05143229 |
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer |
Breast Cancer |
Active, Not Recruiting |